ProQR Therapeutics BV (PRQR) — Cash Flow-to-Debt Ratio
ProQR Therapeutics BV (PRQR) has a Cash Flow-to-Debt Ratio of -0.23x as of June 2026, meaning its operating cash flow of $-12.40 Million could theoretically repay 0% of its total liabilities ($54.05 Million) in one year. See ProQR Therapeutics BV leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ProQR Therapeutics BV Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for ProQR Therapeutics BV across 13 annual periods. For the full cash flow conversion analysis, see PRQR cash flow metrics.
Annual Cash Flow-to-Debt Ratio for ProQR Therapeutics BV (2013–2025)
Year-by-year debt coverage analysis for ProQR Therapeutics BV. Check ProQR Therapeutics BV cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.71x | $-52.79 Million | $74.44 Million | ▼ -60.2% |
| 2024 | -0.44x | $-36.39 Million | $82.22 Million | ▼ -319.0% |
| 2023 | 0.20x | $21.55 Million | $106.59 Million | ▲ +133.0% |
| 2022 | -0.61x | $-68.51 Million | $111.68 Million | ▼ -158.4% |
| 2021 | -0.24x | $-26.01 Million | $109.57 Million | ▲ +74.0% |
| 2020 | -0.91x | $-47.06 Million | $51.61 Million | ▲ +44.8% |
| 2019 | -1.65x | $-43.97 Million | $26.61 Million | ▲ +5.5% |
| 2018 | -1.75x | $-30.68 Million | $17.55 Million | ▲ +17.2% |
| 2017 | -2.11x | $-34.95 Million | $16.54 Million | ▲ +19.2% |
| 2016 | -2.62x | $-34.22 Million | $13.09 Million | ▼ -20.9% |
| 2015 | -2.16x | $-24.23 Million | $11.20 Million | ▼ -5.8% |
| 2014 | -2.04x | $-14.46 Million | $7.07 Million | ▼ -454.9% |
| 2013 | -0.37x | $-2.33 Million | $6.33 Million | — |